Literature DB >> 28169857

Intersection of prognosis and palliation in neurocritical care.

Michael Rubin1, Jordan Bonomo, J Claude Hemphill.   

Abstract

PURPOSE OF REVIEW: Difficult discussions regarding end-of-life care are common in neurocritical care. Because of a patient's neurological impairment, decisions regarding continuing or limiting aggressive care must often be made by patients' families in conjunction with medical providers. This review provides perspective on three major aspects of this circumstance: prognostication, family-physician discussions, and determination of death (specifically as it impacts on organ donation). RECENT
FINDINGS: Numerous studies have now demonstrated that prediction models developed from populations of brain-injured patients may be misleading when applied to individual patients. Early care limitations may lead to the self-fulfilling prophecy of poor outcomes because of care decisions rather than disease course. A shared decision-making approach that emphasizes transmission of information and trust between families and medical providers is ethically appropriate in severely brain-injured patients and as part of the transition to end-of-life palliative care. Standard definitions of death by neurological criteria exist, although worldwide variation and the relationship to organ donation make this complex.
SUMMARY: End-of-life care in patients with severe brain injuries is common and represents a complex intersection of prognostication, family communication, and decision-making. Skills to optimize this should be emphasized in neurocritical care providers.

Entities:  

Mesh:

Year:  2017        PMID: 28169857     DOI: 10.1097/MCC.0000000000000396

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  3 in total

1.  Neurosurgical patients admitted via the emergency department initiating comfort care measures: a prospective cohort analysis.

Authors:  Joseph R Linzey; Rachel Foshee; Sudharsan Srinivasan; Arjun R Adapa; Meghan L Wind; Carina Brake; Badih Junior Daou; Kyle Sheehan; Thomas C Schermerhorn; Teresa L Jacobs; Aditya S Pandey
Journal:  Acta Neurochir (Wien)       Date:  2020-08-21       Impact factor: 2.216

2.  The Curing Coma Campaign: Framing Initial Scientific Challenges-Proceedings of the First Curing Coma Campaign Scientific Advisory Council Meeting.

Authors:  J Javier Provencio; J Claude Hemphill; Jan Claassen; Brian L Edlow; Raimund Helbok; Paul M Vespa; Michael N Diringer; Len Polizzotto; Lori Shutter; Jose I Suarez; Robert D Stevens; Daniel F Hanley; Yama Akbari; Thomas P Bleck; Melanie Boly; Brandon Foreman; Joseph T Giacino; Jed A Hartings; Theresa Human; Daniel Kondziella; Geoffrey S F Ling; Stephan A Mayer; Molly McNett; David K Menon; Geert Meyfroidt; Martin M Monti; Soojin Park; Nader Pouratian; Louis Puybasset; Benjamin Rohaut; Eric S Rosenthal; Nicholas D Schiff; Tarek Sharshar; Amy Wagner; John Whyte; DaiWai M Olson
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

3.  Proceedings of the First Curing Coma Campaign NIH Symposium: Challenging the Future of Research for Coma and Disorders of Consciousness.

Authors:  Jan Claassen; Yama Akbari; Sheila Alexander; Mary Kay Bader; Kathleen Bell; Thomas P Bleck; Melanie Boly; Jeremy Brown; Sherry H-Y Chou; Michael N Diringer; Brian L Edlow; Brandon Foreman; Joseph T Giacino; Olivia Gosseries; Theresa Green; David M Greer; Daniel F Hanley; Jed A Hartings; Raimund Helbok; J Claude Hemphill; H E Hinson; Karen Hirsch; Theresa Human; Michael L James; Nerissa Ko; Daniel Kondziella; Sarah Livesay; Lori K Madden; Shraddha Mainali; Stephan A Mayer; Victoria McCredie; Molly M McNett; Geert Meyfroidt; Martin M Monti; Susanne Muehlschlegel; Santosh Murthy; Paul Nyquist; DaiWai M Olson; J Javier Provencio; Eric Rosenthal; Gisele Sampaio Silva; Simone Sarasso; Nicholas D Schiff; Tarek Sharshar; Lori Shutter; Robert D Stevens; Paul Vespa; Walter Videtta; Amy Wagner; Wendy Ziai; John Whyte; Elizabeth Zink; Jose I Suarez
Journal:  Neurocrit Care       Date:  2021-07-08       Impact factor: 3.210

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.